During the first half of January 2026, the Diisopropyl Ether (DIPE) Del USGC prices started the year on a bearish tone, falling by 4.17% during the first week due to relatively weaker feedstock fundamentals and stable import flow. Isopropyl Alcohol is down by 0.39% while the production cost is trimming as the propylene prices are slipping down. Domestic production and DIPE imports from Germany and Japan poured in supply, keeping the Gulf Coast stocks replenished. End-use demand for DIPE was not pressing in the post-holiday period as solvent formulators and fuel blenders held off buying. The second week ended with prices stable, representing a divergence from the weakening 12-week short-term bearish trend, and this was the case because there had been very subdued changes on the DIPE supply/demand.
Selenis has effectively manufactured recycled PET chips using terephthalic acid sourced from Circ®, a textile-to-textile recycler based in Virginia. The chip production took place through a series of batches at Selenis' pilot plant in San-Giorgio, Italy. By utilizing inputs recovered from polycotton textile waste, Selenis has created high-quality PET chip, which has been further processed into DTY yarn. This yarn will play a crucial role in product development as Circ prepares for additional capsule launches. Selenis is leveraging the success of this initial collaboration phase and is committed to advancing towards an offtake partnership to support Circ's inaugural industrial facility.
Eduardo Santos, Head of Corporate Strategy at Selenis, remarked that the monomer synthesis showed a performance comparable to virgin terephthalic acid. He expressed optimism about the consistent quality of Circ's monomer output and anticipated future commercial success. Santos pointed out that the Circ partnership complements Selenis's existing mission and goals for a more sustainable textile industry. He further stated their anticipation of expanding upon this collaboration and providing support for Circ's forthcoming commercial production trials.
